

# ViroCarb Inc. announces funding to develop a novel oral anti-COVID 19 treatment

TORONTO, ONTARIO, CANADA, March 15, 2022 /EINPresswire.com/ -- ViroCarb Inc. is pleased to announce that it is receiving advisory services and funding of up to \$160,500 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) supporting a research and development project to advance the Company's preclinical development of an innovative oral treatment for COVID-19.

Unlike drugs that target viral components unique to a single virus, ViroCarb's small molecule drug platform disrupts viral RNA processing and blocks the replication of multiple viral families. This MOA translates into a broad-spectrum host cell resistance to known and potentially new emerging viruses and endows a low propensity for drug resistance.

"We are very grateful to NRC IRAP for their support in advancing our ongoing preclinical research program. Our focus is on developing a novel broad-spectrum oral treatment, with a reduced propensity for drug resistance that limits current virus-targeted approaches," said Bharat Tewarie, MD, MBA, ViroCarb's CEO. "Our immediate goal is to develop a most needed effective oral treatment of infections caused by [SARS-COV-2](#) and future emerging variants."

About ViroCarb Inc. ([www.virocarb.com](http://www.virocarb.com))

ViroCarb Inc. is an antiviral company with a paradigm shift drug platform that provides broad-spectrum protection against current and newly emerging pathogenic viruses to overcome the clinical challenges of viral infection.

For more information contact:

Mario Huesca, Ph.D. President & Chief Operating Officer  
ViroCarb Inc  
+1 647-772-9437



ViroCarb Inc.

mailto:mario.huesca@virocarb.com

Visit us on social media:

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/565235720>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.